What a month it has been for Race Oncology shareholders.
The post Up 38% in a month, what’s sparking the recent Race Oncology share price run-up? appeared first on The Motley Fool Australia. –
TheÂ Race Oncology LtdÂ (ASX: RAC) share price had yet another stunning day, leaving the broader index well behind.
At close of trade, the specialty pharmaceutical companyâs shares finished 15.74% ahead at $2.50 each. This means the company’s shares have now risen more than 38% in the past month.
For context, theÂ All Ordinaries IndexÂ (ASX: XAO) closed 0.5% lower to 6,784.3 points today and is now down more than 9% for the month.
Whatâs driving Race Oncology shares forward?
Investors were rallying up the Race Oncology share price today amid the companyâs latest string of announcements, along with positive sentiment.
The board approved the purchase of up to four million Race Oncology shares, which represents 2.5% of its issued capital.
When the news broke, this led shares in the company to finish 11.24% higher on the day.
Furthermore, Race Oncology released aÂ statementÂ highlighting two peer-reviewed abstracts published in the scientific journal, Cancer Research.
Both publications noted the companyâs new preclinical data on the anti-cancer uses of its lead candidate Zantrene.
Again, when Race Oncology provided the update to the ASX, its shares soared 10% before market close.
After that, there was another rush on the company’s shares followingÂ successful resultsÂ from its Zantrene trial.
The clinical data showed that the anti-cancer drug protected the hearts of mice from chemotherapy damage.
This is particularly significant as the company is seeking to capture the âlarge commercial opportunityâ thatâs present for Zantrene.
Lastly, helping the accent of Race Oncology shares is theÂ S&P/ASX 200 Health CareÂ (ASX: XHJ) sector advancing 1.97% today.
About the Race Oncology share price
Despite the strong gains made over the month, the Race Oncology share price is down 30% in 2022.
Based on todayâs price, Race commands aÂ market capitalisationÂ of around $398 million.
The post Up 38% in a month, what’s sparking the recent Race Oncology share price run-up? appeared first on The Motley Fool Australia.
Before you consider Race Oncology Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of June 1 2022
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
ASX 200 healthcare shares provided some pain relief today. Here’s why
Why is the Race Oncology share price soaring 13% today?
Why did the Race Oncology share price rocket 10% today?
Race Oncology share price soars 16% on buyback news
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.